• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2009

View Archived Issues

New venlafaxine prodrugs for depression imparted by Solvay

Read More

CrystaX scientists claim Hsp90 inhibitors and their use in cancer therapy

Read More

Sanofi-aventis presents novel PKB inhibitors for cancer

Read More

Novel PARP inhibitors under development at Abbott for the treatment of cancer

Read More

Indeglitazar, a pan-agonist of PPARs, entering phase II trial for type 2 diabetes mellitus

Read More

Gel and intravaginal ring forms of IQP-0528 are being developed as topical HIV microbicides

Read More

EMEA accepts for review Genmab's Arzerra NDA

Read More

MannKind updates NDA submission status for Afresa

Read More

RegeneRx provides update on phase II RGN-137 trial in venous stasis

Read More

Theravance receives FDA complete response letter for telavancin NDA

Read More

Cephalon intends to make a cash takeover offer to Arana

Read More

DSMB recommends continuation of phase III clinical trial of GTx's toremifene

Read More

MedImmune licenses biologics drug for treating asthma from La Jolla

Read More

Serenity completes phase II clinical trial of CPEX Pharmaceuticals' urology drug

Read More

MabThera approved in the E.U. for patients with chronic lymphocytic leukemia

Read More

AstraZeneca receives FDA complete response letter for Seroquel XR sNDA

Read More

Somaxon receives FDA complete response letter for Silenor

Read More

Phase II study shows potential benefit of erlotinib before cystectomy for bladder cancer

Read More

AZD-0530 inhibits cell growth and migration in human bladder cancer in vitro

Read More

Astellas commences tender offer to acquire outstanding shares of CV Therapeutics

Read More

Nitec completes recruitment in phase III Lodotra trial in rheumatoid arthritis

Read More

FDA approves Symbicort for chronic obstructive pulmonary disease

Read More

The Medicines Company acquires Targanta Therapeutics

Read More

Pharmaxis submits NDA to FDA for Aridol

Read More

Salix receives FDA complete response letter for Metozolv ODT

Read More

Abbott claims new Aurora kinase inhibitors as oncolytic agents

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe